Critical Illness
Conditions
Brief summary
Critical illness represents a complex pathophysiological state characterized by systemic inflammation, oxidative stress, immune dysregulation, and progressive multiorgan dysfunction. In the Intensive Care Unit (ICU) setting, accurate and timely risk stratification remains paramount for optimizing patient outcomes, guiding therapeutic decision-making, and ensuring appropriate allocation of limited healthcare resources .Red cell distribution width (RDW), a quantitative measure of anisocytosis, has emerged as a powerful independent predictor of adverse outcomes across diverse clinical contexts, including sepsis, cardiovascular disease, and general ICU populations . Elevated RDW reflects dysregulated erythropoiesis and is mechanistically linked to chronic inflammation, oxidative stress, nutritional deficiencies, and impaired hematopoietic progenitor cell function .Mean corpuscular hemoglobin concentration (MCHC) represents the average hemoglobin concentration within erythrocytes and provides valuable information regarding red blood cell integrity, hemoglobin synthesis, and oxygen-carrying capacity. Reduced MCHC values are observed in conditions associated with impaired hemoglobin production, while elevated values may indicate hemolysis or red cell dehydration .Emerging evidence suggests that composite hematological ratios may enhance predictive performance compared to individual parameters by integrating complementary physiological information. The RDW:MCHC ratio is a novel biomarker that combines variability in red cell size with hemoglobin concentration, potentially offering a more comprehensive reflection of the underlying pathophysiological derangements characteristic of critical illness
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* • ICU stay of at least 24 hours duration * Available complete blood count (CBC) parameters at the time * pregnant women at any gestational age and postpartum women (up to 6 weeks following delivery) are eligible * Adult patients (≥18 years)
Exclusion criteria
* • Documented hematological malignancies (including leukemia, lymphoma, and myelodysplastic syndromes) * Recent blood transfusion (within 7 days prior to ICU admission)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1. ICU Mortality | From ICU admission to ICU discharge or death, up to 90 days | All-cause mortality during ICU stay, assessed through prospective follow-up from admission until discharge or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ICU Length of Stay | From ICU admission to ICU discharge (assessed up to 90 days) | Duration of intensive care unit admission measured in days from ICU admission until ICU discharge. |
Countries
Egypt
Contacts
Sohag university .faculty of medicine